Absence of adynamic bone disease in African-Americans with CKD Stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio

Clinical Nephrology

Volumn 71, Issue 3, 2009, Pages 267-275

  Fehmi, H ^a   Osman, Y ^a   Bhat, S ^a   Nguyen, K ^a   Daramola, O ^b   Cantor, T ^c   Monier Faugere, M C ^d   Yee, J ^a   Malluche, H H ^d  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b CFA Kidney and Hypertension Center   (United States)

^c Scantibodies Laboratory   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Adynamic bone disease; Intact PTH; PTH ratio; Vitamin D therapy

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; DEMECLOCYCLINE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; RECOMBINANT PARATHYROID HORMONE; VITAMIN D DERIVATIVE; PEPTIDE FRAGMENT; VITAMIN D;

ADULT; AFRICAN AMERICAN; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BONE BIOPSY; BONE DISEASE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PREVALENCE; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; BIOPSY; BLOOD; BONE; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; DISEASE COURSE; ETHNOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PROSPECTIVE STUDY; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL; TREATMENT OUTCOME;

AFRICAN AMERICANS; BIOPSY; BONE AND BONES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VITAMIN D;

EID: 65449169185     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71267     Document Type: Article

References (66)

1. Adragao T, Ferreira A, Frazao J et al. Vascular calcifications and bone turnover in hemodialysis patients. Nephrol Dial Transplant. 2006; 21 (Suppl IV): 292.
2. Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial. 2005; 18: 315-321.
3. 3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int. 1989; 35: 661-669.
4. Bell NH, Williamson BT, Hollis BW, Riggs BL. Effects of race on diurnal patterns of renal conservation of calcium and bone resorption in premenopausal women. Osteoporos Int. 2001; 12: 43-48.
5. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38: 938-942.
6. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
7. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438-441.
8. Cannella G, Bonucci E, Rolla D et al. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-termintravenous calcitriol. Kidney Int. 1994; 46: 1124-1132.
9. Carmen Sanchez M, Auxiliadora Bajo M, Selgas R et al. Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis. 2000; 36: 953-961.
10. Denton J, Freemont AJ, Ball J. Detection of distribution of aluminum in bone. J Clin Pathol. 1984; 37: 136-142.
11. Dressler R, Laut J, Lynn RI, Ginsberg N. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol. 1995; 43: 324-331.
12. Fehmi H, Cantor T, Holcomb J. Increased proportion of 7-84 PTH found in African American ESRD patients versus Caucasians - potential explanation of phenomenon that African Americans with adynamic bone disease have three times higher iPTH values compared to Caucasians. J Am Soc Nephrol. 2006; 17: 785A.
13. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008; 19: 405-412.
14. Frazao JM, Elangovan L, Maung HM et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000; 36: 550-561.
15. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994; 68: 221-228.
16. Fuleihan GE, Gundberg CM, Gleason R et al. Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab. 1994; 79: 1642-1647.
17. Goldner J. A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol. 1938; 14: 237-243.
18. 3 on clinical and biochemical derangements of divalent ions in dialysis patients. Contrib Nephrol. 1980; 18: 42-54.
19. González EA. Vitamin D receptor ligand therapy in chronic kidney disease. Clin Nephrol. 2008; 70: 271-283.
20. Goodman WG. Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis. Semin Dial. 2007; 20: 1-4.
21. Goodman WG, Ramirez JA, Belin TR et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994; 46: 1160-1166.
22. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
23. Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol. 2000; 11: 330-334.
24. Gutierrez OM, Isakova T, Andress DL, Levin A, Wolf M. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int. 2008; 73: 956-962.
25. Hernandez JD, Wesseling K, Salusky IB. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial. 2005; 18: 290-295.
26. Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int. 2000; 57: 282-292.
27. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771-780.
28. Kazama JJ, Omori K, Takahashi N, Ito Y, Maruyama H, Narita I, Gejyo F, Iwasaki Y, Fukagawa M. Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2005; 64: 64-68.
29. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003; 42 (Suppl. 3): S1-201.
30. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008; 168: 397-403.
31. Kuzela DC, Huffer WE, Conger JD, Winter SD, Hammond WS. Soft tissue calcification in chronic dialysis patients. Am J Pathol. 1977; 86: 403-424.
32. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology. 2003; 144: 1135-1138.
33. Lehmann G, Ott U, Kämmerer D, Schütz J, Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5. Clin Nephrol. 2008; 70: 296-305.
34. Lillie PD, Fullmer HM. Histopathologic technique and practical histochemistry. New York: McGraw Hill; 1976.
35. Llach F, Hervas J, Cerezo S. The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis. 1995; 26: 845-851.
36. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 1943-1951.
37. Malluche HH, Faugere MC. Atlas of mineralized bone histology. New York: Karger; 1986.
38. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int. 1992; 42 (Suppl 38): S62-67.
39. Malluche HH, Monier-Faugere MC. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol. 1994; 4: 1631-1642.
40. Malluche HH, Ritz E, Lange H et al. Bone histology in incipient and advanced renal failure. Kidney Int. 1976; 9: 355-362.
41. 3 on bone disease of dialysis patients. Contrib Nephrol. 1980; 18: 98-104.
42. Malluche HH, Matthews C, Faugere MC, Fanti P, Endres DB, Friedler RM. 1,25-Dihydroxy vitamin D maintains bone cell activity, and parathyroid hormonemodulates bone cell number in dogs. Endocrinology. 1986; 119: 1298-1304.
43. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol Dial Transplant. 2004; 19 (Suppl 1): i9-13.
44. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006; 70: 351-357.
45. Mochizuki T, Naganuma S, Tanaka Y, Iwamoto Y, Ishiguro C, Kawashima Y, Maekawa K, Suda A, Akiba T. Prospective comparison of the effects of maxacalcitol and cacitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter randomized crossover study. Clin Nephrol. 2007; 67: 12-19.
46. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2,248 patients. Nephrol Dial Transplant. 1996; 11: 111-120.
47. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001; 60: 1460-1468.
48. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology. 2001; 142: 1386-1392.
49. Pei Y, Hercz G, Greenwood C et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res. 1995; 10: 149-156.
50. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab. 1992; 75: 145-150.
51. Ritz E, Malluche HH, Bommer J, Mehls O, Krempien B. Metabolic bone disease in patients on maintenance hemodialysis. Nephron. 1974; 12: 393-404.
52. Salusky IB, Kuizon BD, Belin TR et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int. 1998; 54: 907-914.
53. Salusky IB, Goodman WG, Kuizon BD et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003; 63: 1801-1808.
54. Sawaya BP, Butros R, Naqvi S et al. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int. 2003; 64: 737-742.
55. 3 users in a haemodialysis population. Nephrol Dial Transplant. 2004; 19: 179-184.
56. Slatopolsky E, Finch J, Clay P et al. Anovel mechanism for skeletal resistance in uremia. Kidney Int. 2000; 58: 753-761.
57. Solal ME, Sebert JL, Boudailliez B et al. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab. 1991; 73: 516-524.
58. Sprague SM, Moe SM. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992; 19: 532-539.
59. Staniforth ME, Cheng SC, Coyne D. Once weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patient. Clin Nephrol. 2005; 63: 454-460.
60. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004; 15: 770-779.
61. Tamez H, Cantor T, Glowacki P, Thadhani R. 1-84 PTH/7-84 Ratio and hemodialysis mortality: linking low bone turnover with adverse outcomes. J Am Soc Nephrol. 2007; 18 (Abstract): 493A.
62. Teng M, Wolf M, Lowrie E, Ofsthun MN, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349: 446-456.
63. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16: 1115-1125.
64. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006; 70: 1858-1865.
65. US Renal Data System. USRDS 2006 Annual Report: Atlas of End-Stage Renal Disease in the United States, NIH and NIDDK. Bethesda, MD; 2006.
66. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72: 1004-1013.